A recombinant antibody molecule, or an α4-binding fragment thereof, comprising a variable heavy chain and a variable light chain, wherein: (a) the variable heavy chain comprises the variable heavy chain framework sequence from IGHVl-f and the CDRs from the VH chain of murine antibody HP1/2, wherein CDR1 comprises the sequence GFNIKDTYM, CDR2 comprises the sequence RIDPASGDTKYDPKFQV and CDR3 comprises the sequence GMWVSTGYALDF; and, (b) the variable light chain comprises the variable light chain framework sequence from IGKV4-1 and the CDRs from the VL chain of murine antibody HP1/2, wherein CDR1 comprises the sequence KASQSVTNDVA, CDR2 comprises the sequence YASNRYT and CDR3 comprises the sequence QQDYSSPYT, wherein: (i) amino acid residues at framework positions 1, 67 and 87 of the variable light chain according to the Kabat numbering scheme are substituted with non-human residues, wherein the non-human residue at framework position 1 is serine, the non-human residue at framework position 67 is tyrosine and the non-human residue at framework position 87 is phenylalanine; and (ii) amino acid residues at framework positions 24 and 94 of the variable heavy chain according to the Kabat numbering scheme are substituted with non-human residues, wherein the non-human residue at framework position 24 is alanine and the non-human residue at framework position 94 is aspartic acid; and wherein the recombinant antibody molecule or the α4-binding fragment thereof binds VLA-4. (a) the variable heavy chain comprises the variable heavy chain framework sequence from IGHVl-f and the CDRs from the VH chain of murine antibody HP1/2, wherein CDR1 comprises the sequence GFNIKDTYM, CDR2 comprises the sequence RIDPASGDTKYDPKFQV and CDR3 comprises the sequence GMWVSTGYALDF; and, (b) the variable light chain comprises the variable light chain framework sequence from IGKV4-1 and the CDRs from the VL chain of murine antibody HP1/2, wherein CDR1 comprises the sequence KASQSVTNDVA, CDR2 comprises the sequence YASNRYT and CDR3 comprises the sequence QQDYSSPYT, wherein: (i) amino acid residues at framework positions 1, 67 and 87 of the variable light chain according to the Kabat numbering scheme are substituted with non-human residues, wherein the non-human residue at framework position 1 is serine, the non-human residue at framework position 67 is tyrosine and the non-human residue at framework position 87 is phenylalanine; and (ii) amino acid residues at framework positions 24 and 94 of the variable heavy chain according to the Kabat numbering scheme are substituted with non-human residues, wherein the non-human residue at framework position 24 is alanine and the non-human residue at framework position 94 is aspartic acid; (i) amino acid residues at framework positions 1, 67 and 87 of the variable light chain according to the Kabat numbering scheme are substituted with non-human residues, wherein the non-human residue at framework position 1 is serine, the non-human residue at framework position 67 is tyrosine and the non-human residue at framework position 87 is phenylalanine; and (ii) amino acid residues at framework positions 24 and 94 of the variable heavy chain according to the Kabat numbering scheme are substituted with non-human residues, wherein the non-human residue at framework position 24 is alanine and the non-human residue at framework position 94 is aspartic acid;